COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors.
作者信息
Baldi Bruno Guedes, Amaral Alexandre Franco, de Figueiredo Braga Colares Phillipe, Kairalla Ronaldo Adib, de Oliveira Martina Rodrigues, Carvalho Carlos Roberto Ribeiro
机构信息
Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
出版信息
Am J Med Genet A. 2020 Dec;182(12):3068-3070. doi: 10.1002/ajmg.a.61877. Epub 2020 Sep 18.
Abstract
摘要
相似文献
1
COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors.新型冠状病毒肺炎与淋巴管平滑肌瘤病：一家参考中心的经验及使用雷帕霉素靶蛋白抑制剂的潜在影响
Am J Med Genet A. 2020 Dec;182(12):3068-3070. doi: 10.1002/ajmg.a.61877. Epub 2020 Sep 18.
2
mTOR signaling in lymphangioleiomyomatosis.淋巴管平滑肌瘤病中的mTOR信号传导
Lymphat Res Biol. 2010 Mar;8(1):33-42. doi: 10.1089/lrb.2009.0019.
3
mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.mTOR治疗在淋巴管平滑肌瘤病中的作用：依维莫司的作用
Expert Rev Respir Med. 2016;10(3):249-60. doi: 10.1586/17476348.2016.1148603.
4
Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?对于等待肺移植的淋巴管平滑肌瘤病女性患者，是否应停用雷帕霉素哺乳动物靶点抑制剂？
Expert Rev Respir Med. 2014 Dec;8(6):657-60. doi: 10.1586/17476348.2014.956728. Epub 2014 Sep 9.
5
The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.mTOR 抑制剂在淋巴管平滑肌瘤病中的疗效和不良反应：系统评价和荟萃分析。
Orphanet J Rare Dis. 2018 Aug 14;13(1):134. doi: 10.1186/s13023-018-0874-7.
6
Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.巴西某医学中心肺移植治疗淋巴管平滑肌瘤病的经验
Lung. 2017 Dec;195(6):699-705. doi: 10.1007/s00408-017-0045-y. Epub 2017 Aug 19.
7
Lymphangioleiomyomatosis: New Treatment Perspectives.淋巴管平滑肌瘤病：新的治疗前景
Lung. 2015 Aug;193(4):467-75. doi: 10.1007/s00408-015-9742-6. Epub 2015 May 17.
8
Pulmonary lymphangioleiomyomatosis: A proposed state of neoplastic senescence.肺淋巴管平滑肌瘤病：一种拟肿瘤性衰老状态。
Med Hypotheses. 2019 Nov;132:109372. doi: 10.1016/j.mehy.2019.109372. Epub 2019 Aug 21.
9
Immunohistological features related to functional impairment in lymphangioleiomyomatosis.淋巴管平滑肌瘤病相关功能障碍的免疫组织学特征。
Respir Res. 2018 May 8;19(1):83. doi: 10.1186/s12931-018-0797-9.
10
Treatment of lymphangioleiomyomatosis and Camões.淋巴管平滑肌瘤病及卡蒙斯病的治疗。
J Bras Pneumol. 2015 Jul-Aug;41(4):295-6. doi: 10.1590/S1806-37132015000400001.
引用本文的文献
1
Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study.中国人群肺淋巴管肌瘤病患者 COVID-19 疫苗接种的安全性和有效性：一项单中心回顾性研究。
Orphanet J Rare Dis. 2024 Jul 3;19(1):247. doi: 10.1186/s13023-024-03260-4.
2
Acute Hypoxemic Respiratory Failure Due to COVID-19 in a Patient With Underlying Lymphangioleiomyomatosis.一名患有潜在淋巴管平滑肌瘤病的患者因新冠病毒病导致急性低氧血症性呼吸衰竭
Cureus. 2022 Jun 12;14(6):e25871. doi: 10.7759/cureus.25871. eCollection 2022 Jun.
3
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.儿科患者使用抗 SARS-CoV-2 单克隆抗体治疗的资格标准：意大利多学会共识声明。
Ital J Pediatr. 2022 Jan 12;48(1):7. doi: 10.1186/s13052-021-01187-1.
4
COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition.淋巴管平滑肌瘤病中的新型冠状病毒肺炎：一项关于雷帕霉素作用机制靶点抑制的结果与影响的国际研究。
Chest. 2022 Jun;161(6):1589-1593. doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 21.
5
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.一位 34 岁来自巴西的女性，因血清血管内皮生长因子-D（VEGF-D）水平升高和 CT 影像上的肺囊肿而被诊断为肺淋巴管肌瘤病，现因 COVID-19 肺炎而就诊。
Am J Case Rep. 2021 Jul 31;22:e932660. doi: 10.12659/AJCR.932660.
6
Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic.坚持还是改变：在新冠疫情期间，依维莫司用于治疗结节性硬化症相关癫痫发作。
Seizure. 2021 Oct;91:271-272. doi: 10.1016/j.seizure.2021.06.035. Epub 2021 Jul 5.
7
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease.COVID-19 与系统性红斑狼疮：炎症性疾病中的经验教训。
Transl Res. 2021 Jun;232:13-36. doi: 10.1016/j.trsl.2020.12.007. Epub 2020 Dec 19.
本文引用的文献
1
Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy.结节性硬化症复合征（TSC）、淋巴管平滑肌瘤病和 COVID-19：意大利 TSC 诊所的经验。
Am J Med Genet A. 2020 Nov;182(11):2479-2485. doi: 10.1002/ajmg.a.61810. Epub 2020 Aug 17.
2
An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?一个悬而未决的问题：将抑制mTor依赖途径作为COVID-19的治疗方法是否合理？
Front Pharmacol. 2020 May 29;11:856. doi: 10.3389/fphar.2020.00856. eCollection 2020.
3
Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.使用 mTOR 抑制剂进行免疫调节以预防 COVID-19 重症：一种超越疫苗和特定抗病毒药物的新型干预策略。
J Med Virol. 2020 Sep;92(9):1495-1500. doi: 10.1002/jmv.26009. Epub 2020 May 22.
4
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.美国胸科学会/日本呼吸学会官方临床实践指南：淋巴管平滑肌瘤病的诊断与管理
Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61. doi: 10.1164/rccm.201607-1384ST.
5
Lymphangioleiomyomatosis.淋巴管平滑肌瘤病。
Clin Chest Med. 2016 Sep;37(3):389-403. doi: 10.1016/j.ccm.2016.04.002.
Zotero 插件